Actuate Therapeutics, Inc. Common stock (ACTU)

NasdaqGM: ACTU · 即時價格 · USD

1.30

-0.24 (-15.58%)

收盤價： Sep 02, 2026, 3:59 PM

1.28

-1.54%

盤後: 7:30 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

-15.58% (1D)

買價	0.8
市值	31.2M
營收 (ttm)	n/a
淨利（ttm）	-20.5M
	0.78
	-0.87
	n/a
	-1.79
P/B (ttm)	31.71
P/S (ttm)	0.00
財報日期	Nov 12, 2026

賣價	1.45
成交量	329,150
20 日平均成交量	348,392
開盤價	1.52
前收盤價	1.54
當日區間	1.30 - 1.55
52 週範圍	0.90 - 9.22
分析師	強<br>購買
目標價	12 (823.08%)
股利	n/a
除息日	n/a

關於 ACTU

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Aug 13, 2024

員工 12

證券交易所 NasdaqGM

股票代號 ACTU

網站 https://actuatetherapeutics.com

完整的公司簡介

財務表現

Actuate Therapeutics Common stock 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -22.23M，較前期減少 -18.54%。

財務報表

分析師預測

根據 3 位分析師的評等，ACTU 的平均評等為「Strong Buy」。12 個月目標價為 12，較最新價格有 823.08% 的上漲空間。

股票預測

財報驚奇

Actuate Therapeutics Common stock 已於 Aug 14, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.2 低於預期 0.00, 年增 33.33% 成長.

下次財報發布

Actuate Therapeutics, Inc. Common stock 的下次財報預計於 Nov 12, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

16 小時前 · Zacks

All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 月前 · Simply Wall St.

Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt

Key Insights The considerable ownership by private equity firms in Actuate Therapeutics indicates that they...

7 月前 · MT Newswires

Actuate Therapeutics Plans to Advance Elraglusib in Ewing Sarcoma After Phase 1 Data

Actuate Therapeutics (ACTU) said Tuesday it plans to advance elraglusib in Ewing sarcoma and potenti

8 月前 · Zacks

Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9 月前 · Zacks

How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%

The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is ques...

第 1 頁，共 2 頁

Actuate Therapeutics, Inc. Common stock (ACTU)